Dalfampridine and Gait in Spinocerebellar Ataxias

Completed · Not applicable · Has a placebo group

Conditions studied: Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6

In brief

Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions for patients with spinocerebellar ataxia.

Key facts

Study ID

NCT01811706

Run by

University of Florida

People needed

20

Starts

2013-02-01

Expected to finish

2013-12-01

Last updated by the study team

2015-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals at age 18 years or older.
• Individuals who can provide the informed consent
• Genetic confirmed definite spinocerebellar ataxias (SCA)
• Able to complete two trials of the timed 25-foot walk at screening

You may not qualify if…

• Patients who has severe ataxia and unable to ambulate.
• Any orthopedic condition that would affect motor performance.
• Patients with secondary ataxia from general medical disorders
• Individuals who have major psychiatric disorders that prevents compliance
• History of epilepsy
• Patients with active drug or alcohol use or dependence that would interfere with adherence to study requirements
• Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

Where it is running

• University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.